EUVIMEDEUVIMED entdecken
Fallbericht

Kidney Transplantation From a Heterozygous CLDN19 Carrier in a Child With FHHNC : A 2‐Year Follow‐Up

Hakan Erdoğan iD, Mahmut Esat Danışoğlu iD, Hüseyin Çelik iD, Murat Şamlı iD, Bülent Oktay iD

Pediatric Transplantation · 2026

DOI: 10.1111/petr.70495 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Pediatric Transplantation, 2026. Verfasst von Hakan Erdoğan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Nephrology, Bursa Faculty of Medicine, City Hospital, University of Health Sciences, Bursa, Türkiye. Hauptthemen laut MEDLINE: Kidney Transplantation, Claudins, Nephrocalcinosis, Hypercalciuria. Die Arbeit nennt 15 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Familial hypomagnesemia with hypercalciuria and nephrocalcinosis is a rare autosomal recessive tubulopathy caused by mutations in CLDN16 or CLDN19 , leading to progressive chronic kidney disease. While kidney transplantation is the definitive treatment, the safety of using living‐related heterozygous carrier donors remains debated due to potential subclinical tubular dysfunction. We report the 2‐year follow‐up of a pediatric patient with FHHNC and a CLDN19 mutation who received a graft from his heterozygous carrier mother. Case Report A male patient presented at 3 months of age with nephrocalcinosis, hypercalciuria, and hypomagnesemia. Genetic analysis confirmed a homozygous CLDN19 (G179S) mutation. Consistent with the CLDN19 phenotype, the patient exhibited severe ocular involvement, including high myopia and macular coloboma. He progressed to end‐stage kidney disease by age 15 and underwent living‐related kidney transplantation from his mother (a heterozygous carrier) at age 16. Pre‐operative donor evaluation showed normal renal function without proteinuria, hypercalciuria, nephrolithiasis, or nephrocalcinosis.

Results

At 24 months post‐transplantation, graft function remained stable with a serum creatinine of 1.22 mg/dL and a 24‐h creatinine clearance of 94 mL/min/1.73 m 2 . Metabolic abnormalities were fully corrected; serum magnesium stabilized at 1.89 mg/dL without supplementation, the urinary calcium/creatinine ratio normalized (2.6 to 0.06), and proteinuria decreased from 2580 mg/day to 324 mg/day. The heterozygous donor maintained stable renal function (24‐h creatinine clearance 86 mL/min/1.73 m 2 ) without proteinuria, nephrolithiasis, or metabolic complications during follow‐up.

Conclusions

Given the shortage of deceased donor organs, heterozygous parents may be considered suitable donors for children with FHHNC, provided they undergo comprehensive genetic, biochemical, and radiological evaluation to exclude evidence of tubular dysfunction. However, this conclusion should be limited to carefully selected donors, and longer‐term follow‐up is required to establish the safety of kidney donation in heterozygous CLDN19 carriers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kidney TransplantationClaudinsNephrocalcinosisHypercalciuriaRenal Tubular Transport, Inborn ErrorsMagnesium DeficiencyHumansMaleHeterozygoteFollow-Up StudiesMutationAdolescentLiving DonorsInfantTreatment Outcome

Stichwörter der Autor:innen

CLDN19FHHNCheterozygous donorhypomagnesemiakidney transplantationmacular coloboma

Substanzen

ClaudinsCLDN19 protein, human

Autor:innen und Institutionen

  • Department of Pediatric Nephrology, Bursa Faculty of Medicine, City Hospital, University of Health Sciences, Bursa, Türkiye.
  • Department of Urology, Kidney Transplantation, Acıbadem Bursa Hospital, Bursa, Türkiye.
  • Department of Nephrology and Kidney Transplantation, Acıbadem Bursa Hospital, Bursa, Türkiye.
  • Department of Urology and Kidney Transplantation, Acıbadem Bursa Hospital, Bursa, Türkiye.

ORCID-Profile: Hakan Erdoğan, Mahmut Esat Danışoğlu, Hüseyin Çelik, Murat Şamlı, Bülent Oktay

Zitieren

APA

Erdoğan, H., Danışoğlu, M. E., Çelik, H., Şamlı, M., & Oktay, B. (2026). Kidney Transplantation From a Heterozygous CLDN19 Carrier in a Child With FHHNC : A 2‐Year Follow‐Up. Pediatric Transplantation. https://doi.org/10.1111/petr.70495

Vancouver

Erdoğan H, Danışoğlu ME, Çelik H, Şamlı M, Oktay B. Kidney Transplantation From a Heterozygous CLDN19 Carrier in a Child With FHHNC : A 2‐Year Follow‐Up. Pediatric Transplantation. 2026. doi:10.1111/petr.70495

BibTeX
@article{Erdoan2026,
  author = {Erdoğan, Hakan and Danışoğlu, Mahmut Esat and Çelik, Hüseyin and Şamlı, Murat and Oktay, Bülent},
  title = {Kidney Transplantation From a Heterozygous CLDN19 Carrier in a Child With FHHNC : A 2‐Year Follow‐Up},
  journal = {Pediatric Transplantation},
  year = {2026},
  doi = {10.1111/petr.70495}
}
Kostenlos starten →